
2. Marre M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–278


13. Montanya E et al, A Review of Efficacy and Safety Data Regarding the Use of Liraglutide, a Once-Daily Human Glucagon-Like Peptide 1 Analogue, in the Treatment of Type 2 Diabetes Mellitus

14. Bode B et al, An overview of the pharmacokinetics, efficacy and safety of liraglutide


16. Pratley Richard E et al. One year of Liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomized, parallel-group, open-label trial. The International Journal of Clinical Practice 2011;65,4:397-407


22. Buse John et al, Liraglutide is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse event: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. J Clin Endocrinol Metab. 2011;96(6):1695-1702
33. Davies M J et al, Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on metformin monotherapy in type 2 diabetes mellitus.
35. King Allen B et al, Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C < 8%. Endocr Pract 2013;19(1):64-72
37. Jendle J. et al, Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity and Metabolism 2009;11:1163-1172
41. C. Kapitza et al, Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin Diabetes, Obesity and Metabolism 15:642-649, 2013
42. Juris J. Meier et al, Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial, Diabetes Care 2015;38:1263–1273
55. Internal calculation based on IMS Midas Quantum data, January 2014
56. Novo Nordisk Victoza® (liraglutide) SmPC, 2012
59. EMA reviews diabetes medicine canagliflozin EMA/267042/2016
60. Poster number 0223-PD, Presented at the World Diabetes Congress, 30 November–4 December 2015, Vancouver, Canada
61. Twigg S. et.al, Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis, Journal of Diabetes •• (2016)
62. William J. V., PhD et.al, Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients with Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents, Clinical Therapeutics/Volume xx, Number x, 2011